<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617721</url>
  </required_header>
  <id_info>
    <org_study_id>3930</org_study_id>
    <nct_id>NCT00617721</nct_id>
  </id_info>
  <brief_title>Markers of Defective Membrane Remodelling in Scott-like Syndromes</brief_title>
  <official_title>Defect in Cell Stimulation and Unexplained hemorrhagesMarkers Related to Membrane Remodelling in the Prognosis Scott-like Syndormes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Louis Pasteur University, Strasbourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aventis, Génopôle d'Evry.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: Identification of the gene(s) involved in plasma membrane remodelling.
      Identification of the circulating markers affected by the defective membrane remodelling in a
      collection of families with unexplained provoked hemorrhages and evaluation of their
      prognosis value in the assessment of the hemostatic cellular response.Hypothesis: Scott
      syndrome is rare a familial disorder characterized by provoked haemorrages in homozygous-type
      patients due to isolated membrane remodelling deficiency. Membrane remodelling is necessary
      for cellular hemostatic responses.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2008</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">29</enrollment>
  <condition>Unexplained Isolated Provoked Hemorrhages</condition>
  <condition>Familial Bleeding Disorder</condition>
  <condition>Scott Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patients with unexplained bleeding disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood withdrawal</intervention_name>
    <description>Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, white cells, DNA (when the family is informative)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with unexplained bleeding disorder
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with unexplained provoked hemorrhages (surgery, tooth extraction, birth …),
             and associated with reduced prothrombin consomption (residual prothrombine in serum &gt;
             à 5%).

          -  Family members of the patients defined above, with or without unexplained hemorrhages
             (symptomatic or not).

          -  Patient's approval based on detailed information given by the pratician

        Exclusion Criteria:

          -  Patients with primary hemostasis defect or defective blood coagulation factor(s)
             possibly explaining the bleeding disorder.

          -  Anémia,

          -  patients known to be affected by Factor V New York .

          -  Patients enrolled in a previous clinical study, the exclusion period of which is not
             yet completed. - Collaboration to the study rejected by the patient

          -  Patients that are not registered for medical care social insurance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lélia GRUNEBAUM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère, Service d'Hématologie Biologique</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire d'Hémostase et d'Immunologie, Centre Hospitalier</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire d'Hématologie, Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire d'Hématologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Biologique, Hôpital Pierre Zobda Quitman</name>
      <address>
        <city>Fort de France</city>
        <zip>97261</zip>
        <country>Martinique</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Martinique</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <last_update_submitted>June 16, 2016</last_update_submitted>
  <last_update_submitted_qc>June 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Defective gene(s) in plasma membrane remodelling.</keyword>
  <keyword>Scott syndrome,</keyword>
  <keyword>Reduced prothrombin consumption,</keyword>
  <keyword>Circulating biomakers of scott syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

